{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=32",
    "query": {
      "condition": "Safety Study",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 33591,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:58:06.548Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03989349",
      "title": "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate-to-Severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 787,
      "start_date": "2019-06-30",
      "completion_date": "2022-09-26",
      "has_results": true,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03989349"
    },
    {
      "nct_id": "NCT00812955",
      "title": "Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\"Bad Cholesterol\") and Triglycerides",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "ABT-143",
          "type": "DRUG"
        },
        {
          "name": "simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2008-11",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-10-03",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 129,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00812955"
    },
    {
      "nct_id": "NCT02349555",
      "title": "Nutritional Supplement Impact on Metabolic Parameters",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Other Endocrine/Nutritional/Metabolic Disorder"
      ],
      "interventions": [
        {
          "name": "Nutritional Supplement Blend",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Pharmanex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-27",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • Logan, Utah",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Logan",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349555"
    },
    {
      "nct_id": "NCT03847909",
      "title": "A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 1 (PH1)",
        "Primary Hyperoxaluria Type 2 (PH2)",
        "Kidney Diseases",
        "Urologic Diseases",
        "Genetic Disease"
      ],
      "interventions": [
        {
          "name": "DCR-PHXC",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2019-10-28",
      "completion_date": "2021-06-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-22",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847909"
    },
    {
      "nct_id": "NCT06535399",
      "title": "Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986369",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2024-08-15",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 3,
      "location_summary": "Chandler, Arizona • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06535399"
    },
    {
      "nct_id": "NCT07677514",
      "title": "A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "H021 Enteric-coated Tablets Low-dose Group",
          "type": "DRUG"
        },
        {
          "name": "H021 Enteric-coated Tablets High-dose Group",
          "type": "DRUG"
        },
        {
          "name": "Placebo Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu Carephar Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 156,
      "start_date": "2026-07-12",
      "completion_date": "2027-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 3,
      "location_summary": "Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Lighthouse PT",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07677514"
    },
    {
      "nct_id": "NCT03495206",
      "title": "Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stroke, Acute",
        "Intracranial Hemorrhages"
      ],
      "interventions": [
        {
          "name": "Y-2(Edaravone And Borneol) Sublingual Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yantai YenePharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-10-25",
      "completion_date": "2021-02",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 1,
      "location_summary": "Peoria, Illinois",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03495206"
    },
    {
      "nct_id": "NCT01011049",
      "title": "Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Vaccine USP Trivalent Types A and B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 1250,
      "start_date": "2009-09",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 44,
      "location_summary": "Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011049"
    },
    {
      "nct_id": "NCT00179738",
      "title": "A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CC5013",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2005-04",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2005-11-23",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 6,
      "location_summary": "Berkeley, California • Tampa, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179738"
    },
    {
      "nct_id": "NCT04642638",
      "title": "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Infection",
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
        "COVID-19 Disease"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1307,
      "start_date": "2020-11-30",
      "completion_date": "2022-09-13",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-11-19T09:58:06.548Z",
      "location_count": 16,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04642638"
    }
  ]
}